세계의 말초성 T세포 림프종(PCTL) 시장 보고서(2025년)

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas that develop from mature T-cells, a type of white blood cell crucial for immune function. PTCL can affect the lymph nodes, spleen, bone marrow, liver, and other organs, with symptoms including swollen lymph nodes, fever, night sweats, unexplained weight loss, skin rashes, and persistent fatigue.

The main types of PTCL include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma, and other subtypes. PTCL-NOS is a cancer originating from mature T-cells that do not fit into specific classifications. Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell therapy, and radiation therapy. The drugs used are classified into histone deacetylase (HDAC) inhibitors, monoclonal antibodies, alkylating agents, antimetabolites, and other categories. These medications are administered through oral and injectable routes and are utilized by various end users, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The peripheral T-cell lymphoma market research report is one of a series of new reports from The Business Research Company that provides peripheral T-cell lymphoma market statistics, including the peripheral T-cell lymphoma industry global market size, regional shares, competitors with the peripheral T-cell lymphoma market share, detailed peripheral T-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the peripheral T-cell lymphoma industry. This peripheral T-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral t-cell lymphoma market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising awareness of rare lymphomas, emergence of monoclonal antibodies, early orphan drug designations, growth in hematologic cancer research, increasing adoption of stem cell transplants, improvements in diagnostic accuracy, expansion of oncology healthcare infrastructure and early immunotherapy innovations.

The peripheral t-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $0.77 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to advancements in targeted therapies, increasing adoption of personalized medicine, growth in immunotherapy applications, robust pipeline of innovative drugs, rising healthcare investments in emerging markets, expansion of patient access programs, integration of artificial intelligence in diagnostics, regulatory incentives for orphan drugs and growing focus on combination therapies. Major trends in the forecast period include development of novel biologics, advancements in gene editing technologies, adoption of liquid biopsy diagnostics, integration of artificial intelligence in treatment planning, innovations in CAR-T cell therapy, advancements in next-generation sequencing, use of nanotechnology for drug delivery, personalized vaccine development, emergence of bispecific antibodies and automation in clinical trial processes.

The forecast of 5.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of novel Histone deacetylase inhibitors inhibitors and flow cytometry reagents sourced from the UK and Belgium, exacerbating oncology treatment expenses and limiting access to targeted therapies. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of lymphoma is expected to drive the growth of the peripheral T-cell lymphoma (PTCL) market. Lymphoma is a type of cancer that originates in the lymphatic system, a key part of the body's immune system. The high occurrence of lymphoma is linked to genetic predisposition, environmental exposures, viral infections such as the Epstein-Barr virus, immunodeficiency conditions, and lifestyle factors such as smoking and obesity. Peripheral T-cell lymphoma contributes to lymphoma progression by arising from mature T-cells, leading to aggressive disease behavior, immune system dysfunction, and lower treatment responsiveness compared to other lymphoma subtypes. For example, according to the American Cancer Society's Facts and Figures, the estimated number of new non-Hodgkin lymphoma cases remained at 80,550 in both 2023 and 2024. As a result, the high incidence of lymphoma is fueling the expansion of the PTCL market.

Leading companies in the PTCL market are prioritizing the development of innovative treatments, such as dihydrofolate reductase inhibitors, to enhance treatment effectiveness and improve patient outcomes. These inhibitors work by blocking the activity of dihydrofolate reductase, an enzyme crucial for DNA synthesis and cell replication. For instance, in December 2024, Fresenius Kabi AG, a Germany-based pharmaceutical company, launched Pralatrexate Injection, a generic equivalent to Folotyn, for treating relapsed or refractory PTCL. This introduction expands the company's oncology portfolio, offering clinicians and patients a high-quality, cost-effective treatment option. The injection is available in 20 mg/1 mL and 40 mg/2 mL single-dose vials and received accelerated approval based on overall response rate, with continued approval dependent on confirmatory trials.

In August 2024, Citius Pharmaceuticals Inc., a US-based pharmaceutical company specializing in treatments for relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL), merged with TenX Keane Acquisition to establish Citius Oncology Inc. This merger aims to create a standalone oncology-focused company, advancing the commercialization of Lymphir and expanding its oncology pipeline. TenX Keane Acquisition Corp. is a US-based company focused on raising capital through an initial public offering (IPO) to acquire or merge with an existing business.

Major players in the peripheral T-cell lymphoma market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Company Limited, BeiGene Ltd., Daiichi Sankyo Company Limited, HUYA Bioscience International LLC, Zymeworks Inc., Genor Biopharma Co. Ltd., Kura Oncology Inc., Acrotech Biopharma LLC, Spectrum Pharmaceuticals Inc., Verastem Inc., Astellas Pharma Inc., Autolus Therapeutics plc.

North America was the largest region in the peripheral T-cell lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peripheral T-cell lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peripheral T-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral T-cell lymphoma market consists of revenues earned by entities by providing services such as diagnosis and screening services, treatment services, hospital and specialty care services, clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral T-cell lymphoma market also includes sales of corticosteroids, anthracyclines, vinca alkaloids, and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peripheral T-Cell Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peripheral t-cell lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peripheral t-cell lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peripheral t-cell lymphoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS); Angioimmunoblastic T- Cell Lymphoma (AITL); Anaplastic Large Cell Lymphoma (ALCL); Adult T- Cell Leukaemia Or Lymphoma (ATLL); Enteropathy-Associated T- Cell Lymphoma ( EATL); Hepatosplenic T- Cell Lymphoma; Other Types
• 2) By Treatment Type: Chemotherapy; Target Therapy; Immunotherapy; Stem Cell Therapy; Radiation Therapy
• 3) By Drug Class: Histone Deacetylase (HDAC) Inhibitors; Monoclonal Antibodies; Alkylating Angents; Antimetabolites; Other Drug Class
• 4) By Route Of Administration: Oral; Injectable
• 5) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Center; Research Institute
• Subsegments:
• 1) By Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS): Cutaneous PTCL; Systemic PTCL
• 2) By Angioimmunoblastic T-Cell Lymphoma (AITL): Classical AITL; Variant AITL
• 3) By Anaplastic Large Cell Lymphoma (ALCL): Systemic ALCL; Cutaneous ALCL
• 4) By Adult T-Cell Leukaemia Or Lymphoma (ATLL): Acute ATLL; Chronic ATLL; Smoldering ATLL; Lymphoma Type ATLL
• 5) By Enteropathy-Associated T-Cell Lymphoma (EATL): Type 1 EATL; Type 2 EATL
• 6) By Hepatosplenic T-Cell Lymphoma: Hepatic Type; Splenic Type
• 7) By Other Types: Subcutaneous T-Cell Lymphoma; Lymphomatoid Granulomatosis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bristol Myers Squibb Company; AstraZeneca plc; Novartis AG; Eli Lilly and Company; Eisai Co. Ltd.; Kyowa Kirin Co. Ltd.; Takeda Pharmaceutical Company Limited; BeiGene Ltd.; Daiichi Sankyo Company Limited; HUYA Bioscience International LLC; Zymeworks Inc.; Genor Biopharma Co. Ltd.; Kura Oncology Inc.; Acrotech Biopharma LLC; Spectrum Pharmaceuticals Inc.; Verastem Inc.; Astellas Pharma Inc.; Autolus Therapeutics plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peripheral T-Cell Lymphoma Market Characteristics

3. Peripheral T-Cell Lymphoma Market Trends And Strategies

4. Peripheral T-Cell Lymphoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Peripheral T-Cell Lymphoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peripheral T-Cell Lymphoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peripheral T-Cell Lymphoma Market Growth Rate Analysis
• 5.4. Global Peripheral T-Cell Lymphoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peripheral T-Cell Lymphoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peripheral T-Cell Lymphoma Total Addressable Market (TAM)

6. Peripheral T-Cell Lymphoma Market Segmentation

• 6.1. Global Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
• Angioimmunoblastic T- Cell Lymphoma (AITL)
• Anaplastic Large Cell Lymphoma (ALCL)
• Adult T- Cell Leukaemia Or Lymphoma (ATLL)
• Enteropathy-Associated T- Cell Lymphoma ( EATL)
• Hepatosplenic T- Cell Lymphoma
• Other Types
• 6.2. Global Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Target Therapy
• Immunotherapy
• Stem Cell Therapy
• Radiation Therapy
• 6.3. Global Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Histone Deacetylase (HDAC) Inhibitors
• Monoclonal Antibodies
• Alkylating Angents
• Antimetabolites
• Other Drug Class
• 6.4. Global Peripheral T-Cell Lymphoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.5. Global Peripheral T-Cell Lymphoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Center
• Research Institute
• 6.6. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous PTCL
• Systemic PTCL
• 6.7. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Angioimmunoblastic T-Cell Lymphoma (AITL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical AITL
• Variant AITL
• 6.8. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Anaplastic Large Cell Lymphoma (ALCL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic ALCL
• Cutaneous ALCL
• 6.9. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Adult T-Cell Leukaemia Or Lymphoma (ATLL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute ATLL
• Chronic ATLL
• Smoldering ATLL
• Lymphoma Type ATLL
• 6.10. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Enteropathy-Associated T-Cell Lymphoma (EATL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 EATL
• Type 2 EATL
• 6.11. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Hepatosplenic T-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatic Type
• Splenic Type
• 6.12. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous T-Cell Lymphoma
• Lymphomatoid Granulomatosis

7. Peripheral T-Cell Lymphoma Market Regional And Country Analysis

• 7.1. Global Peripheral T-Cell Lymphoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peripheral T-Cell Lymphoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peripheral T-Cell Lymphoma Market

• 8.1. Asia-Pacific Peripheral T-Cell Lymphoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peripheral T-Cell Lymphoma Market

• 9.1. China Peripheral T-Cell Lymphoma Market Overview
• 9.2. China Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peripheral T-Cell Lymphoma Market

• 10.1. India Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peripheral T-Cell Lymphoma Market

• 11.1. Japan Peripheral T-Cell Lymphoma Market Overview
• 11.2. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peripheral T-Cell Lymphoma Market

• 12.1. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peripheral T-Cell Lymphoma Market

• 13.1. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peripheral T-Cell Lymphoma Market

• 14.1. South Korea Peripheral T-Cell Lymphoma Market Overview
• 14.2. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peripheral T-Cell Lymphoma Market

• 15.1. Western Europe Peripheral T-Cell Lymphoma Market Overview
• 15.2. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peripheral T-Cell Lymphoma Market

• 16.1. UK Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peripheral T-Cell Lymphoma Market

• 17.1. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peripheral T-Cell Lymphoma Market

• 18.1. France Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peripheral T-Cell Lymphoma Market

• 19.1. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peripheral T-Cell Lymphoma Market

• 20.1. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peripheral T-Cell Lymphoma Market

• 21.1. Eastern Europe Peripheral T-Cell Lymphoma Market Overview
• 21.2. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peripheral T-Cell Lymphoma Market

• 22.1. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peripheral T-Cell Lymphoma Market

• 23.1. North America Peripheral T-Cell Lymphoma Market Overview
• 23.2. North America Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peripheral T-Cell Lymphoma Market

• 24.1. USA Peripheral T-Cell Lymphoma Market Overview
• 24.2. USA Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peripheral T-Cell Lymphoma Market

• 25.1. Canada Peripheral T-Cell Lymphoma Market Overview
• 25.2. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peripheral T-Cell Lymphoma Market

• 26.1. South America Peripheral T-Cell Lymphoma Market Overview
• 26.2. South America Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peripheral T-Cell Lymphoma Market

• 27.1. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peripheral T-Cell Lymphoma Market

• 28.1. Middle East Peripheral T-Cell Lymphoma Market Overview
• 28.2. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peripheral T-Cell Lymphoma Market

• 29.1. Africa Peripheral T-Cell Lymphoma Market Overview
• 29.2. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peripheral T-Cell Lymphoma Market Competitive Landscape And Company Profiles

• 30.1. Peripheral T-Cell Lymphoma Market Competitive Landscape
• 30.2. Peripheral T-Cell Lymphoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Peripheral T-Cell Lymphoma Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Eisai Co. Ltd.
• 31.3. Kyowa Kirin Co. Ltd.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. BeiGene Ltd.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. HUYA Bioscience International LLC
• 31.8. Zymeworks Inc.
• 31.9. Genor Biopharma Co. Ltd.
• 31.10. Kura Oncology Inc.
• 31.11. Acrotech Biopharma LLC
• 31.12. Spectrum Pharmaceuticals Inc.
• 31.13. Verastem Inc.
• 31.14. Astellas Pharma Inc.
• 31.15. Autolus Therapeutics plc

32. Global Peripheral T-Cell Lymphoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peripheral T-Cell Lymphoma Market

34. Recent Developments In The Peripheral T-Cell Lymphoma Market

35. Peripheral T-Cell Lymphoma Market High Potential Countries, Segments and Strategies

• 35.1 Peripheral T-Cell Lymphoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peripheral T-Cell Lymphoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peripheral T-Cell Lymphoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer